Primary Immune Deficiency Diseases (PIDD)
Conditions
Brief summary
The purpose of this study is to investigate the efficacy, safety, tolerability, and pharmacokinetic profile of the investigational medicinal product (IMP) and to determine, on the basis of historical control data, how it compares with other 10% intravenous immunoglobulin (IGIV) products currently licensed in North America for the treatment of subjects with primary immune deficiency diseases (PIDD).
Interventions
BIOLOGICAL10% IGIV
300-900 mg/kg
Sponsors
Evolve Biologics
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
2 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Subject has a confirmed clinical diagnosis of a PIDD, which requires treatment with IGIV: * Subject/guardian has provided written informed consent (and assent, as applicable). * Subject is between the ages of 2 and 70 years. * Subject has received regular IGIV therapy at 21- or 28-day (±4 days) intervals for at least three consecutive months at a dose between 300-900 mg/kg/month prior to Screening or; * Subject has received commercial SCIG at a dose of 300-900 mg/kg/month on any dosing schedule for at least 12 consecutive weeks prior to Screening. Subjects on SCIG must have received and tolerated IGIV treatment prior to SCIG treatment. * Subject has a documented trough of ≥500 mg/dL in the 6 months prior to screening. * Females of childbearing potential must be willing to use an effective form of birth control (eg, oral contraceptives) for the duration of the study, per IRB/REB guidelines. * Subject agrees to comply with the requirements of the protocol.
Exclusion criteria
* Subject has secondary immunodeficiency. * Subject has history of thrombotic events, such as deep vein thrombosis, myocardial infarction, cerebrovascular accident, pulmonary embolism, etc within the year prior to screening. * Subject has had an immune globulin associated arterial or venous thrombotic/thromboembolic event (TEE) within 7 days of infusion or a TEE that is not associated with an immune globulin within one year of screening. * Subject has received blood products (except for IGIV, SCIG, or albumin) within 6 months of screening. * Subject has anemia (≤8.5 g/dL). * Subject has levels of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3.0 times the upper limit of normal (ULN). * Subject has severe neutropenia (≤1000 neutrophils per mm3). * Subject is receiving other immunosuppressive or immunomodulatory drugs or chemotherapy. * Subject is taking or has taken within the four weeks prior to screening prednisone at ≥0.15 mg/kg/day for more than 10 days. * Subject has ever had a severe anaphylactic reaction to a blood or IgG product. * Subject has lymphoid malignancy, leukemia, or any other history of malignancy within the past five years, except squamous cell or basal cell carcinoma of the skin (not melanoma). * Subject has hypoalbuminemia, protein-losing enteropathy, or proteinuria greater than 300 mg/24 hours except for subjects with documented orthostatic proteinuria. * Subject has immunoglobulin A (IgA) deficiency with known antibodies to IgA. * Female who is pregnant, breastfeeding, or planning a pregnancy during the course of the study (women who become pregnant during the study will be withdrawn from the study). * Any condition that is likely to interfere with evaluation of IMP or satisfactory conduct of the trial in the PI's opinion. * Subjects who may not be compliant or have a history of non-compliance in the opinion of the PI.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Acute Serious Bacterial Infection (SBI) Rate | 1 year | The primary efficacy endpoint was the rate of acute SBI (pneumonia, bacteremia and septicemia, osteomyelitis/septic arthritis, bacterial meningitis, visceral abscess) per participant during the 12-month study observation period |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immunoglobulin G (IgG) Trough Concentration | Up to 1 year per participant | The average serum total IgG trough concentration |
| Days Unable to Perform Daily Activities | Up to 1 year per participant | The number of days out of work/school/daycare or unable to perform normal daily activities due to infections |
| Therapeutic IgG Levels | Up to 1 year per participant | Number of participants with maintenance of stable IgG levels |
Countries
Canada, United States
Contacts
STUDY_DIRECTORMark Krause
Therapure Biopharma
Participant flow
Recruitment details
A total of 63 patients were enrolled between September 2017 and August 2020 at 13 sites across the United States and Canada.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Customized Age, Continuous | 49.4 Years STANDARD_DEVIATION 14.3 |
| Body Mass Index | 30.14 kg/m2 STANDARD_DEVIATION 7.72 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 13 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) White | 48 Participants |
| Sex: Female, Male Female | 5 Participants |
| Sex: Female, Male Male | 21 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 48 | 0 / 15 |
| other Total, other adverse events | 44 / 48 | 15 / 15 |
| serious Total, serious adverse events | 4 / 48 | 0 / 15 |
Outcome results
None listed